Browsing: Cognitive/neurodegenerative disorders
Dopamine agonists and prodrugs taken to treat Parkinson’s disease may cause impulse control disorders in over half the patients they are prescribed to.
Hannah Churchill reports on the Alzheimer’s Society Annual Conference (22–23 May, London, UK), including preventative risk factors, technology and dementia, as well as drug repurposing.
According to a large study, individuals with Type 2 diabetes may have an increased risk of being diagnosed with Parkinson’s disease later in life.
An independent data monitoring committee has advised that lanabecestat is unlikely to meet primary endpoints, leading to the decision to discontinue trials.
In this NCTalks podcast, Sharon Salt speaks to Wendy Weidner to learn more about Alzheimer’s Disease International and the global situation of dementia.
This week’s industry news round-up reveals the latest updates around spinal muscular atrophy, Parkinson’s disease and acute stroke.
Researchers have synthesized an artificial human prion for the first time, in an attempt to understand their structure, manner of replication and infectivity.
Whilst at the Alzheimer’s Society Annual Conference 2018, Sharon Salt spoke with Simon Lovestone to hear more about his talk on big data and dementia.
Alzheimer’s Society has worked with an expert taskforce to develop goals and detailed recommendations for research into dementia prevention, diagnosis, intervention and care by 2025.